Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bolt Biotherapeutics Inc BOLT

Healthcare Biotechnology
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating... see more

Recent & Breaking News (NDAQ:BOLT)

Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

GlobeNewswire May 25, 2023

Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 11, 2023

Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

GlobeNewswire April 26, 2023

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire March 29, 2023

Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies

GlobeNewswire March 29, 2023

Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting

GlobeNewswire March 14, 2023

Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference

GlobeNewswire February 28, 2023

Bolt Biotherapeutics to Present at February Investor Conferences

GlobeNewswire February 1, 2023

Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

GlobeNewswire December 14, 2022

Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 10, 2022

Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting

GlobeNewswire November 7, 2022

Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference

GlobeNewswire November 1, 2022

Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

GlobeNewswire August 31, 2022

Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire August 10, 2022

Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022

GlobeNewswire May 27, 2022

Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

GlobeNewswire May 12, 2022

Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference

GlobeNewswire April 7, 2022

Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights

GlobeNewswire March 30, 2022

Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022

GlobeNewswire March 8, 2022

Bolt Biotherapeutics to Participate in Upcoming February Conferences

GlobeNewswire February 2, 2022